Free Trial

Oric Pharmaceuticals (NASDAQ:ORIC) Trading 10% Higher - What's Next?

Oric Pharmaceuticals logo with Medical background

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) rose 10% during trading on Wednesday . The company traded as high as $11.12 and last traded at $11.16. Approximately 363,326 shares changed hands during trading, a decline of 54% from the average daily volume of 789,991 shares. The stock had previously closed at $10.14.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ORIC. HC Wainwright reissued a "buy" rating and issued a $21.00 price objective on shares of Oric Pharmaceuticals in a research note on Monday, May 5th. Oppenheimer reduced their price objective on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating on shares of Oric Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Wedbush restated an "outperform" rating and set a $20.00 target price on shares of Oric Pharmaceuticals in a research report on Monday, June 23rd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Oric Pharmaceuticals presently has an average rating of "Buy" and an average target price of $19.17.

Read Our Latest Report on Oric Pharmaceuticals

Oric Pharmaceuticals Stock Performance

The firm's 50 day simple moving average is $7.70 and its 200 day simple moving average is $7.78. The firm has a market capitalization of $917.82 million, a price-to-earnings ratio of -5.76 and a beta of 1.54.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.09. As a group, sell-side analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Insider Activity

In related news, Director Angie You bought 26,597 shares of the firm's stock in a transaction on Friday, June 20th. The shares were bought at an average price of $9.39 per share, with a total value of $249,745.83. Following the completion of the transaction, the director directly owned 26,597 shares of the company's stock, valued at $249,745.83. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Dominic Piscitelli sold 32,466 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total transaction of $340,893.00. Following the sale, the chief financial officer owned 68,317 shares in the company, valued at $717,328.50. The trade was a 32.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,000 shares of company stock worth $416,289. Corporate insiders own 6.82% of the company's stock.

Institutional Trading of Oric Pharmaceuticals

Several hedge funds have recently made changes to their positions in ORIC. KLP Kapitalforvaltning AS purchased a new position in Oric Pharmaceuticals during the 4th quarter valued at about $50,000. BNP Paribas Financial Markets acquired a new stake in shares of Oric Pharmaceuticals during the 4th quarter worth about $71,000. Arizona State Retirement System acquired a new stake in shares of Oric Pharmaceuticals in the first quarter worth approximately $56,000. PNC Financial Services Group Inc. lifted its position in Oric Pharmaceuticals by 22.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after buying an additional 2,520 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of Oric Pharmaceuticals during the fourth quarter worth $118,000. Institutional investors and hedge funds own 95.05% of the company's stock.

About Oric Pharmaceuticals

(Get Free Report)

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

Read More

Should You Invest $1,000 in Oric Pharmaceuticals Right Now?

Before you consider Oric Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.

While Oric Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines